دورية أكاديمية
Serum thyroid hormone antibodies are frequent in patients with polyglandular autoimmune syndrome type 3, particularly in those who require thyroxine treatment
| العنوان: | Serum thyroid hormone antibodies are frequent in patients with polyglandular autoimmune syndrome type 3, particularly in those who require thyroxine treatment |
|---|---|
| المؤلفون: | Roberto Vita, Maria Giulia Santaguida, Camilla Virili, Maria Segni, Marina Galletti, Mattia Mandolfino, Flavia Di Bari, Marco Centanni, Salvatore Benvenga |
| المساهمون: | Vita, Roberto, Santaguida, MARIA GIULIA, Virili, Camilla, Segni, Maria, Galletti, Marina, Mandolfino, Mattia, Di Bari, Flavia, Centanni, Marco, Benvenga, Salvatore |
| بيانات النشر: | Frontiers Research Foundation Lausanne |
| سنة النشر: | 2017 |
| المجموعة: | Sapienza Università di Roma: CINECA IRIS |
| مصطلحات موضوعية: | thyroid hormone antibodie, chronic autoimmune thyroiditi, chronic atrophic gastriti, non-segmental vitiligo, celiac disease |
| الوصف: | Polyglandular autoimmune syndrome (PAS) type 3 consists of autoimmune thyroid disease (AITD) coexisting with ≥1 non-thyroidal autoimmune disease (NTAID) other than Addison’s disease and hypoparathyroidism. We evaluated the prevalence and repertoire of thyroid hormones antibodies (THAb) in PAS-3 patients. Using a radioimmunoprecipation technique, we measured THAb (T3IgM, T3IgG, T4IgM, and T4IgG) in 107 PAS-3 patients and 88 controls (patients with AITD without any NTAID). Based on the selective coexistence of AITD with one NTAID (chronic autoimmune gastritis, non-segmental vitiligo or celiac disease), patients were divided into group 1 (chronic autoimmune gastritis positive, n = 64), group 2 (non-segmental vitiligo positive, n = 24), and group 3 (celiac disease positive, n = 15). At least one of the four THAb was detected in 45 PAS-3 patients (42.1%) and 28 controls (31.8%, P = 0.14), with similar rates in the three PAS-3 groups. The rates of T3Ab, T4Ab, and T3 + T4Ab were similar in groups 1 and 2, while in group 3, T3Ab was undetected (P = 0.02). In PAS-3 patients, the rate of levothyroxine treatment was greater in THAb-positive patients compared to THAb-negative patients (76.7 vs. 56.1%, P = 0.03, RR = 1.4, 95% CI 1.03–1.81). Not unexpectedly, levothyroxine daily dose was significantly higher in group 1 and group 3, namely in patients with gastrointestinal disorders, compared to group 2 (1.9 ± 0.4 and 1.8 ± 0.3 vs. 1.5 ± 0.2 μg/kg body weight, P = 0.0005 and P = 0.004). Almost half of PAS-3 patients have THAb, whose repertoire is similar if chronic autoimmune gastritis or celiac disease is present. A prospective study would confirm whether THAb positivity predicts greater likelihood of requiring levothyroxine treatment. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/28894436; info:eu-repo/semantics/altIdentifier/wos/WOS:000408500600001; volume:8; numberofpages:6; journal:FRONTIERS IN ENDOCRINOLOGY; http://hdl.handle.net/11573/1204612Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85028608670 |
| DOI: | 10.3389/fendo.2017.00212 |
| الإتاحة: | https://doi.org/10.3389/fendo.2017.00212Test http://hdl.handle.net/11573/1204612Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F3BED9A3 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fendo.2017.00212 |
|---|